Repligen (NASDAQ:RGEN) Now Covered by Analysts at Wolfe Research

Wolfe Research assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm issued a peer perform rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on the company. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, UBS Group reduced their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 11.8 %

NASDAQ:RGEN traded down $16.79 during midday trading on Thursday, reaching $125.64. The company had a trading volume of 466,512 shares, compared to its average volume of 659,362. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of -361.50, a PEG ratio of 4.36 and a beta of 0.96. The stock’s fifty day simple moving average is $141.59 and its 200-day simple moving average is $144.78. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $0.23 earnings per share. On average, sell-side analysts anticipate that Repligen will post 1.44 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. IHT Wealth Management LLC acquired a new position in Repligen during the 3rd quarter worth approximately $407,000. Janus Henderson Group PLC boosted its stake in shares of Repligen by 848.4% during the 3rd quarter. Janus Henderson Group PLC now owns 23,700 shares of the biotechnology company’s stock worth $3,528,000 after acquiring an additional 21,201 shares in the last quarter. Cinctive Capital Management LP purchased a new stake in shares of Repligen during the 3rd quarter worth approximately $1,118,000. Paloma Partners Management Co lifted its stake in Repligen by 267.7% in the 3rd quarter. Paloma Partners Management Co now owns 6,932 shares of the biotechnology company’s stock valued at $1,032,000 after buying an additional 5,047 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Repligen in the 3rd quarter valued at approximately $2,080,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.